These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34221977)

  • 21. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
    Yang W; Men P; Xue H; Jiang M; Luo Q
    Front Oncol; 2020; 10():197. PubMed ID: 32211312
    [No Abstract]   [Full Text] [Related]  

  • 22. Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis.
    Hu J; Tian R; Ma Y; Zhen H; Ma X; Su Q; Cao B
    Front Oncol; 2021; 11():645245. PubMed ID: 34123795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.
    Wu K; Yi M; Qin S; Chu Q; Zheng X; Wu K
    Exp Hematol Oncol; 2019; 8():26. PubMed ID: 31673481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study.
    Li H; Zheng Y; Xu P; Li Z; Kuang Y; Feng X; He J; Li J; Chen X; Bai L; Tang KJ
    Front Pharmacol; 2023; 14():1142016. PubMed ID: 37124234
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials.
    Jin C; Qi J; Wang Q; Pu C; Tan M
    Front Oncol; 2023; 13():1158690. PubMed ID: 37124488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Petrelli F; Morelli AM; Luciani A; Ghidini A; Solinas C
    Target Oncol; 2021 Sep; 16(5):553-568. PubMed ID: 34224061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions.
    Hong B; Zheng J; Chen R; Zheng C; Du B; Ni R; Yang J
    Drug Saf; 2023 Dec; 46(12):1313-1322. PubMed ID: 37934397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.
    Alifu M; Tao M; Chen X; Chen J; Tang K; Tang Y
    Front Oncol; 2023; 13():1146905. PubMed ID: 37397392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis.
    Sun YM; Li W; Chen ZY; Wang Y
    Front Oncol; 2021; 11():651553. PubMed ID: 34745932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
    Chen X; Zhang Z; Hou X; Zhang Y; Zhou T; Liu J; Lin Z; Fang W; Yang Y; Ma Y; Huang Y; Zhao H; Zhang L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Da L; Teng Y; Wang N; Zaguirre K; Liu Y; Qi Y; Song F
    Front Pharmacol; 2019; 10():1671. PubMed ID: 32082164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
    Parlati L; Sakka M; Retbi A; Bouam S; Hassani L; Meritet JF; Rufat P; Bonnefont-Rousselot D; Batista R; Terris B; Bellanger A; Thabut D; Vozy A; Spano JP; Coriat R; Goldwasser F; Aractingi S; Sogni P; Pol S; Mallet V; ;
    JHEP Rep; 2023 Dec; 5(12):100880. PubMed ID: 38074948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis.
    Osipov A; Lim SJ; Popovic A; Azad NS; Laheru DA; Zheng L; Jaffee EM; Wang H; Yarchoan M
    Clin Cancer Res; 2020 Sep; 26(18):4842-4851. PubMed ID: 32586938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.